SELLAS Life Sciences (SLS)
Market Price (5/11/2026): $5.0 | Market Cap: $706.3 MilSector: Health Care | Industry: Biotechnology
SELLAS Life Sciences (SLS)
Market Price (5/11/2026): $5.0Market Cap: $706.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.63 | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -28 Mil Stock price has recently run up significantly6M Rtn6 month market price return is 215%, 12M Rtn12 month market price return is 221% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.8% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40% Key risksSLS key risks include [1] a critical dependency on the success of its pivotal Phase 3 REGAL trial for drug candidate GPS and [2] overcoming intense competition in the saturated Acute Myeloid Leukemia market to achieve market adoption. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.63 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -28 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 215%, 12M Rtn12 month market price return is 221% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.8% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40% |
| Key risksSLS key risks include [1] a critical dependency on the success of its pivotal Phase 3 REGAL trial for drug candidate GPS and [2] overcoming intense competition in the saturated Acute Myeloid Leukemia market to achieve market adoption. |
Qualitative Assessment
AI Analysis | Feedback
1. Advancement of SLS009 Clinical Program.
SELLAS initiated enrollment in a randomized Phase 2 trial evaluating SLS009 (tambiciclib) for newly diagnosed, first-line acute myeloid leukemia (AML) patients in the US and Europe in March 2026. This followed positive prior Phase 2 results in relapsed/refractory AML, where SLS009 in combination with azacitidine/venetoclax achieved an overall response rate of 33%, with a 40% ORR observed at the 30mg BIW dose.
2. Positive Preclinical Data for SLS009.
In March 2026, SELLAS announced the presentation of preclinical data at the 2026 AACR Conference, highlighting the potent activity of SLS009 in AML. The data demonstrated that SLS009 lowered the apoptotic threshold in AML cells by suppressing survival pathways, with the IC50 decreasing from 50 nM to approximately 20 nM with repeated exposure. Notably, activity was observed in AML models harboring ASXL1 and TP53 mutations, which are typically associated with high resistance.
Show more
Stock Movement Drivers
Fundamental Drivers
The 32.9% change in SLS stock from 1/31/2026 to 5/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.77 | 5.01 | 32.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 108 | 141 | -23.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLS | 32.9% | |
| Market (SPY) | 3.6% | 44.2% |
| Sector (XLV) | -6.9% | 36.2% |
Fundamental Drivers
The 175.3% change in SLS stock from 10/31/2025 to 5/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.82 | 5.01 | 175.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 99 | 141 | -30.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLS | 175.3% | |
| Market (SPY) | 5.5% | 22.5% |
| Sector (XLV) | 0.3% | 13.9% |
Fundamental Drivers
The 223.2% change in SLS stock from 4/30/2025 to 5/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.55 | 5.01 | 223.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 74 | 141 | -47.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLS | 223.2% | |
| Market (SPY) | 30.4% | 18.6% |
| Sector (XLV) | 4.0% | 17.3% |
Fundamental Drivers
The 256.6% change in SLS stock from 4/30/2023 to 5/10/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.41 | 5.01 | 256.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | |
| P/S Multiple | 29.2 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 21 | 141 | -85.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLS | 256.6% | |
| Market (SPY) | 78.7% | 13.2% |
| Sector (XLV) | 13.0% | 14.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SLS Return | -5% | -57% | -55% | -2% | 262% | 31% | -15% |
| Peers Return | -30% | -42% | 107% | -56% | 10% | 22% | -51% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| SLS Win Rate | 42% | 50% | 50% | 33% | 58% | 40% | |
| Peers Win Rate | 27% | 40% | 57% | 40% | 48% | 64% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| SLS Max Drawdown | -8% | -67% | -63% | -52% | -12% | -8% | |
| Peers Max Drawdown | -39% | -61% | -43% | -62% | -53% | -16% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: KURA, TCRX, AGEN, MRKR, IMMX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | SLS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -17.5% | -18.8% |
| % Gain to Breakeven | 21.2% | 23.1% |
| Time to Breakeven | 11 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.7% | -9.5% |
| % Gain to Breakeven | 80.7% | 10.5% |
| Time to Breakeven | 162 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -63.1% | -6.7% |
| % Gain to Breakeven | 171.2% | 7.1% |
| Time to Breakeven | 1007 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.3% | -24.5% |
| % Gain to Breakeven | 225.6% | 32.4% |
| Time to Breakeven | 1245 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.6% | -33.7% |
| % Gain to Breakeven | 52.9% | 50.9% |
| Time to Breakeven | 27 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -29.1% | -19.2% |
| % Gain to Breakeven | 41.1% | 23.7% |
| Time to Breakeven | 3 days | 105 days |
In The Past
SELLAS Life Sciences's stock fell -17.5% during the 2025 US Tariff Shock. Such a loss loss requires a 21.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SLS | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -44.7% | -9.5% |
| % Gain to Breakeven | 80.7% | 10.5% |
| Time to Breakeven | 162 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -63.1% | -6.7% |
| % Gain to Breakeven | 171.2% | 7.1% |
| Time to Breakeven | 1007 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.3% | -24.5% |
| % Gain to Breakeven | 225.6% | 32.4% |
| Time to Breakeven | 1245 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -34.6% | -33.7% |
| % Gain to Breakeven | 52.9% | 50.9% |
| Time to Breakeven | 27 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -29.1% | -19.2% |
| % Gain to Breakeven | 41.1% | 23.7% |
| Time to Breakeven | 3 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -57.5% | -12.2% |
| % Gain to Breakeven | 135.2% | 13.9% |
| Time to Breakeven | 59 days | 62 days |
| 2013 Taper Tantrum | ||
| % Loss | -40.2% | -0.2% |
| % Gain to Breakeven | 67.3% | 0.2% |
| Time to Breakeven | 112 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -49.6% | -17.9% |
| % Gain to Breakeven | 98.5% | 21.8% |
| Time to Breakeven | 158 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -52.9% | -15.4% |
| % Gain to Breakeven | 112.3% | 18.2% |
| Time to Breakeven | 1243 days | 125 days |
In The Past
SELLAS Life Sciences's stock fell -17.5% during the 2025 US Tariff Shock. Such a loss loss requires a 21.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About SELLAS Life Sciences (SLS)
AI Analysis | Feedback
Here are 1-2 brief analogies for SELLAS Life Sciences (SLS):
- Think of them as a Moderna or BioNTech, but for novel cancer immunotherapies instead of vaccines, still aiming for their big breakthrough.
- A focused biotech company, similar to a younger Genentech, specializing in developing new cancer immunotherapy drugs.
AI Analysis | Feedback
```html- galinpepimut-S (GPS): A cancer immunotherapeutic agent targeting Wilms tumor 1, in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 for ovarian cancer.
- nelipepimut-S: A cancer immunotherapy targeting human epidermal growth factor receptor 2, in Phase 2b clinical trials for early-stage breast cancer.
AI Analysis | Feedback
SELLAS Life Sciences (SLS) is a late-stage biopharmaceutical company primarily focused on the research and development of novel cancer immunotherapies. Its lead product candidates, galinpepimut-S (GPS) and nelipepimut-S, are currently in various phases of clinical trials (Phase III, Phase 1/2, and Phase 2b).
As their product candidates are still in development and have not yet received regulatory approval for commercial sale, SELLAS Life Sciences does not currently have major customers that purchase its therapeutic products. The company's activities are centered on advancing its pipeline through clinical trials.
While SELLAS has a strategic collaboration with Merck & Co., Inc. (NYSE: MRK) for the evaluation of GPS in combination with pembrolizumab, this relationship is a development partnership rather than a customer-vendor arrangement for product sales.
AI Analysis | Feedback
nullAI Analysis | Feedback
Dr. Angelos M. Stergiou, President and Chief Executive Officer
Dr. Stergiou is the founder of SELLAS Life Sciences Group, Inc.. Prior to founding SELLAS in 2012, he co-founded Genesis Life Sciences, Ltd. (now Genesis Research), where he served as President and Chief Operating Officer from 2009 to 2011. From 2002 to 2009, he held international positions of increasing responsibility in pharmaceutical and biotechnology companies, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International, and Anavex Life Sciences. Dr. Stergiou led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, and holds a patent on the technology.
John T. Burns, Vice President Finance, Corporate Controller and Interim Principal Accounting Officer
John T. Burns serves as the Vice President Finance, Corporate Controller, and Interim Principal Accounting Officer at SELLAS Life Sciences.
Dragan Cicic, Senior Vice President, Clinical Development
Dr. Cicic has 20 years of experience in the biopharmaceutical industry. Before joining SELLAS, he was a Senior Vice President, Clinical Lead, at Klus Pharma, where he led the global clinical development of targeted solid cancer biologicals. He also held senior management positions at Actinium Pharmaceuticals, launching key clinical trials in hematologic malignancies. Dr. Cicic received his medical degree from the University of Belgrade and an MBA from the Wharton School of the University of Pennsylvania.
Stacy Yeung, Vice President, Associate General Counsel, and Head of Compliance
Stacy Yeung has 20 years of relevant experience and was promoted to Vice President, Associate General Counsel, and Head of Compliance as of March 8, 2024, leading the Company's legal and compliance functions.
AI Analysis | Feedback
```htmlHere are the key risks to SELLAS Life Sciences (SLS):
- Clinical Trial and Regulatory Approval Risk: As a late-stage biopharmaceutical company, SELLAS Life Sciences' success is heavily dependent on the successful outcome of its ongoing clinical trials and the subsequent receipt of regulatory approvals for its product candidates. The lead candidate, galinpepimut-S (GPS), is in Phase III for acute myeloid leukemia and Phase 1/2 for ovarian cancer, while nelipepimut-S is in Phase 2b for early-stage breast cancer. There is no guarantee that these clinical trials will demonstrate sufficient efficacy and safety, or that regulatory bodies will grant approval, which could significantly jeopardize the company's future prospects.
- Pipeline Concentration Risk: The company's future value and viability are substantially tied to the successful development and commercialization of a limited number of product candidates, primarily galinpepimut-S (GPS) and nelipepimut-S. A failure in the development, clinical trials, or regulatory approval process of one or both of these key candidates would have a disproportionately severe negative impact on SELLAS Life Sciences, given the lack of a broad and diversified product pipeline.
AI Analysis | Feedback
null
AI Analysis | Feedback
For SELLAS Life Sciences (symbol: SLS), the addressable markets for their main products are as follows:
- Galinpepimut-S (GPS) for Acute Myeloid Leukemia (AML): The global acute myeloid leukemia treatment market was valued at approximately USD 3.91 billion in 2025. It is projected to grow to USD 9.79 billion by 2034. North America represented approximately 41% of this global market in 2025.
- Galinpepimut-S (GPS) for Ovarian Cancer: The global ovarian cancer treatment market (specifically for High-Grade vs. Low-Grade Serous Ovarian Cancer) was valued at USD 3.012 billion in 2025 and is expected to grow to USD 5.703 billion by 2034. The United States accounted for nearly USD 1,922 million of this market in 2024.
- Nelipepimut-S for Early-Stage Breast Cancer: The global breast cancer market was valued at USD 38.41 billion in 2025 and is projected to reach USD 89.91 billion by 2034. North America dominated the breast cancer market in 2024.
AI Analysis | Feedback
SELLAS Life Sciences (SLS) is a late-stage biopharmaceutical company with no current product revenue; therefore, its future revenue growth over the next 2-3 years is primarily dependent on the successful clinical development, regulatory approval, and commercialization of its lead product candidates. Key drivers of future revenue growth for SELLAS Life Sciences include:- Commercialization of Galinpepimut-S (GPS) for Acute Myeloid Leukemia (AML) in the United States: The most significant anticipated driver is the potential U.S. regulatory approval and subsequent commercial launch of galinpepimut-S (GPS). GPS is currently in a pivotal Phase 3 REGAL trial for AML as maintenance therapy following second complete remission. Analysts' forecasts for substantial revenue beginning in 2026, reaching billions in subsequent years, indicate an expectation of successful product launch and sales for GPS.
- Advancement and Potential Commercialization of SLS009 in AML: The progression and potential regulatory approval of SLS009, a highly selective CDK9 inhibitor, for AML indications represent another crucial revenue driver. SLS009 has demonstrated positive Phase 2 data in relapsed/refractory AML, and a new randomized Phase 2 trial evaluating it in newly diagnosed, first-line AML patients commenced enrollment in early 2026. Successful outcomes from these trials could lead to accelerated regulatory approvals and market entry within the projected timeframe.
- Expansion into New Geographic Markets and Additional Cancer Indications through Strategic Collaborations: SELLAS's strategic partnerships could drive future revenue by expanding the market reach and therapeutic applications of its product candidates. This includes the existing collaboration with Merck & Co. to evaluate GPS in combination with pembrolizumab across various hematologic malignancies and solid tumors, which could lead to expanded indications. Furthermore, the agreement with IMPACT-AML to extend the SLS009 clinical program into Europe aims to broaden patient access and establish a foundation for potential European commercialization.
- Achievement of Milestone Payments from Strategic Partnerships: As a clinical-stage company, SELLAS's revenue growth can also be fueled by milestone payments triggered by the successful achievement of clinical development, regulatory, or commercial milestones from its various strategic collaborations. For example, the agreement with 3D Medicines for GPS commercialization in China includes potential future bonuses up to $191.5 million.
AI Analysis | Feedback
Share Issuance
- SELLAS completed multiple registered direct offerings in 2024, resulting in approximately $66.3 million in net proceeds through the issuance of common stock, pre-funded warrants, and accompanying warrants.
- In 2025, the company received a total of approximately $54.6 million in gross proceeds from the immediate exercise of existing warrants.
- Subsequent to December 31, 2025, SELLAS received approximately $42.6 million in cash proceeds from common stock warrant exercises.
Inbound Investments
- SELLAS received approximately $42.6 million in cash from common stock warrant exercises after December 31, 2025.
- The company received approximately $54.6 million in gross proceeds from warrant exercises in September and October 2025.
- In January 2025, SELLAS closed a $25 million registered direct offering with a single healthcare-focused institutional investor.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| SELLAS Life Sciences Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SLS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.42 |
| Mkt Cap | 0.4 |
| Rev LTM | 8 |
| Op Inc LTM | -32 |
| FCF LTM | -52 |
| FCF 3Y Avg | -27 |
| CFO LTM | -48 |
| CFO 3Y Avg | -25 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 62.1% |
| Rev Chg 3Y Avg | 9.7% |
| Rev Chg Q | -54.8% |
| QoQ Delta Rev Chg LTM | -5.8% |
| Op Inc Chg LTM | -2.9% |
| Op Inc Chg 3Y Avg | -10.0% |
| Op Mgn LTM | -284.3% |
| Op Mgn 3Y Avg | -916.4% |
| QoQ Delta Op Mgn LTM | -44.7% |
| CFO/Rev LTM | -159.9% |
| CFO/Rev 3Y Avg | -807.8% |
| FCF/Rev LTM | -164.8% |
| FCF/Rev 3Y Avg | -835.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 8.0 |
| P/Op Inc | -4.8 |
| P/EBIT | -3.1 |
| P/E | -2.3 |
| P/CFO | -7.3 |
| Total Yield | -20.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -48.2% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.3% |
| 3M Rtn | 26.1% |
| 6M Rtn | 42.2% |
| 12M Rtn | 47.4% |
| 3Y Rtn | -6.7% |
| 1M Excs Rtn | -8.8% |
| 3M Excs Rtn | 19.4% |
| 6M Excs Rtn | 26.2% |
| 12M Excs Rtn | 17.8% |
| 3Y Excs Rtn | -83.0% |
Price Behavior
| Market Price | $5.01 | |
| Market Cap ($ Bil) | 0.7 | |
| First Trading Date | 03/12/2008 | |
| Distance from 52W High | -15.9% | |
| 50 Days | 200 Days | |
| DMA Price | $4.96 | $3.05 |
| DMA Trend | up | up |
| Distance from DMA | 1.1% | 64.3% |
| 3M | 1YR | |
| Volatility | 87.3% | 90.6% |
| Downside Capture | 1.26 | 0.67 |
| Upside Capture | 337.78 | 234.15 |
| Correlation (SPY) | 42.4% | 18.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.21 | 3.04 | 2.66 | 1.82 | 1.34 | 0.78 |
| Up Beta | 1.57 | 1.94 | 1.86 | 1.10 | 0.39 | 0.68 |
| Down Beta | -10.98 | 1.79 | 1.85 | 1.24 | 0.90 | 0.44 |
| Up Capture | 261% | 414% | 477% | 554% | 505% | 170% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 11 | 20 | 33 | 66 | 124 | 348 |
| Down Capture | 908% | 356% | 245% | 127% | 127% | 97% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 21 | 29 | 56 | 117 | 353 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLS | |
|---|---|---|---|---|
| SLS | 187.4% | 90.6% | 1.57 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 18.3% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 17.9% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 11.2% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -14.7% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 16.4% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 10.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLS | |
|---|---|---|---|---|
| SLS | -9.1% | 94.0% | 0.36 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 17.9% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 20.2% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 6.1% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 0.8% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 18.7% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 15.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLS | |
|---|---|---|---|---|
| SLS | -59.5% | 130.3% | -0.10 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 8.9% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 10.7% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 3.4% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 3.6% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 8.7% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 7.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/19/2026 | -8.5% | -4.8% | -4.0% |
| 11/12/2025 | -2.0% | 2.0% | 36.9% |
| 8/12/2025 | -3.7% | 5.6% | 17.4% |
| 3/20/2025 | -0.8% | -4.1% | 6.6% |
| 11/13/2024 | 0.0% | -2.4% | -31.3% |
| 8/13/2024 | 0.8% | 10.1% | 11.8% |
| 3/28/2024 | 5.9% | 32.7% | 19.8% |
| 11/9/2023 | -0.2% | 1.2% | 13.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 8 | 7 |
| # Negative | 13 | 11 | 12 |
| Median Positive | 1.2% | 7.8% | 17.4% |
| Median Negative | -8.5% | -17.2% | -13.5% |
| Max Positive | 10.4% | 49.4% | 176.0% |
| Max Negative | -53.7% | -58.0% | -66.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/19/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Patient Enrollment | 40 | ||||||
Prior: Q3 2025 Earnings Reported 11/12/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Trial Enrollment Initiation | |||||||
| 2025 REGAL Trial Final Analysis | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kalin, Katherine Bach | Direct | Buy | 11212025 | 1.59 | 63,400 | 100,806 | 165,996 | Form | |
| 2 | Van, Nostrand Robert L | Direct | Buy | 6132025 | 1.48 | 10,000 | 14,800 | 30,192 | Form | |
| 3 | Wasman, Jane | Direct | Buy | 6022025 | 1.69 | 20,000 | 33,800 | 51,376 | Form | |
| 4 | Kalin, Katherine Bach | Direct | Buy | 5222025 | 1.80 | 20,000 | 36,000 | 73,800 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.